Engineered immune cells take on COVID-19: a novel vaccine approach
NCT ID NCT04299724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests a new type of COVID-19 vaccine made from artificial antigen presenting cells (aAPC). The vaccine is designed to teach the body's T cells to recognize and attack the SARS-CoV-2 virus. The study includes healthy volunteers and people with mild COVID-19, and will check for side effects and measure immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Covid-19/aAPC vaccine (artificial antigen presenting cells made with lentiviral vector)
- What this could lead to
- If successful, this vaccine could help prevent or treat severe COVID-19 pneumonia by training the immune system to attack the virus.
- What could go wrong
- This is an early Phase 1 trial with only 100 participants, so safety and effectiveness are not yet proven. The vaccine uses a lentiviral vector, which may cause unexpected immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREAT AND PREVENT COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China